UB Paderborn / Katalog / Suche / in CDI

Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population

Acta virologica (Anglickâa verze), 2008, Vol.52 (4), p.261

2008

Volltextzugriff (PDF)

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)

Annals of oncology, 2005-10, Vol.16 (10), p.1683-1687

2005

Volltextzugriff (PDF)

Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group

Journal of clinical oncology, 2005-03, Vol.23 (7), p.1522-1529

2005

Volltextzugriff (PDF)

SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification

Annals of oncology, 2023-06, Vol.34, p.S165-S166

2023

Volltextzugriff (PDF)

FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

Annals of oncology, 2019-04, Vol.30, p.ii67-ii67

2019

Volltextzugriff (PDF)

P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases

Neuro-oncology (Charlottesville, Va.), 2022-09, Vol.24 (Supplement_2), p.ii81-ii81

2022

Volltextzugriff (PDF)

1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

Annals of oncology, 2023-10, Vol.34, p.S767-S767

2023

Volltextzugriff (PDF)

1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

Annals of oncology, 2022-09, Vol.33, p.S1025

2022

Volltextzugriff (PDF)

Economic Burden of Clinical Trials in Lung Cancer in a German Comprehensive Cancer Center

Lung cancer (Amsterdam, Netherlands), 2017-06, Vol.108, p.134-139

2017

Volltextzugriff (PDF)

Lymphocyte-predominant and classical Hodgkin's lymphoma - comparison of outcomes

European journal of haematology, 2005-07, Vol.75 (s66), p.106-110

2005

Volltextzugriff (PDF)

1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

Annals of oncology, 2022-09, Vol.33, p.S1327

2022

Volltextzugriff (PDF)

52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

Annals of oncology, 2022-04, Vol.33, p.S56-S57

2022

Volltextzugriff (PDF)

EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S451-S452

2022

Volltextzugriff (PDF)

EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S456

2022

Volltextzugriff (PDF)

Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels

Annals of oncology, 2017-09, Vol.28, p.v302-v302

2017

Volltextzugriff (PDF)

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S490-S490

2018

Volltextzugriff (PDF)

OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S247-S247

2019

Volltextzugriff (PDF)

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study

Annals of oncology, 2005-08, Vol.16 (8), p.1359-1365

2005

Volltextzugriff (PDF)

SORAVE trial: Phase I sorafenib and everolimus in solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS170-TPS170

2010

Volltextzugriff (PDF)

The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13613-e13613

2011

Volltextzugriff (PDF)

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-122-LB-122

2012

Volltextzugriff (PDF)

Review of general anesthesia procedures in ophthalmology

Česká a slovenská oftalmologie, 1998-07, Vol.54 (4), p.263

1998

Volltextzugriff (PDF)

184TiPFIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma

Annals of hematology, 2005-08, Vol.84 (8), p.517-525

2005

Volltextzugriff (PDF)

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group

Blood, 2006-11, Vol.108 (11), p.97-97

2006

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)

Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group

SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification

FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases

1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

Economic Burden of Clinical Trials in Lung Cancer in a German Comprehensive Cancer Center

Lymphocyte-predominant and classical Hodgkin's lymphoma - comparison of outcomes

1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels

P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study

SORAVE trial: Phase I sorafenib and everolimus in solid tumors

The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

Review of general anesthesia procedures in ophthalmology

184TiPFIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group

Suchergebnisse filtern